Navigation Links
Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
Date:4/25/2013

on will take place over the next three months, the Company is cautiously optimistic that it has found a way to control JCV," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics.  "The common mechanism of action utilized by IkT-001Pro enables treatment for bacterial and viral infectious disease, and the application of this medication could be suitable for many types of infections."

About JC Virus and Progressive Multifocal Leukoencephalopathy (PML)

The John Cunningham virus (JCV) is a type of human polyomavirus. It was isolated in 1971 from a patient with progressive multifocal leukoencephalopathy (PML). Human polyomaviruses, like JC and BK, cause PML and other diseases only in the context of immunodeficiency, as in AIDS, or drug-related immune suppression, either for treatment of autoimmune disease, cancer or for solid organ transplant maintenance. JCV infection is very common in the general population, with roughly 60 percent of adult humans likely to have been exposed to the virus; most people acquire JCV in childhood or adolescence. (1)  When immunodeficiency or immunosuppression allows JCV to 'reactivate', the virus preferentially migrates to the brain, destroying oligodendrocytes and astrocytes. This lytic infection leads to cognitive and motor dysfunction (the syndrome PML) and is fatal in 50 percent or more of patients.   The best approach to treating the disease is to attack the virus before it enters the brain. IkT-001Pro blocks viral entry into host cells, and therefore could suppress an active JCV infection in at risk patients prior to virus migration into the brain.  There is no currently approved treatment for PML.

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial and viral infectious diseases.  Its pipeline of validated targets u
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MENLO PARK, Calif. , July ... DMPI) ("DelMar" "the company") announced today that the company,s board ... from December 31 to June 30. Accordingly, DelMar will file ... Jeffrey Bacha , president and CEO of ... important step in achieving our goal of obtaining a senior ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... 2011 Bacterin International Holdings, Inc. (NYSE ... developer of revolutionary bone graft material and anti-microbial coatings ... first quarter ended March 31, 2011.  Since the beginning ... the number of medical facilities in which its products ...
... Technologies Inc. (OTCBB: MDCE), a children,s healthcare service ... children,s health and wellness center. The City of Dongguan ... of choice to establish the Company,s first flagship pediatric ... chosen because of its progressive economics, recording 10.3% GDP ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 2Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 3Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 4Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 5Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 6Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 7Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 8Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 9Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 2Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 3
(Date:7/25/2014)... Las Vegas, NV (PRWEB) July 25, 2014 ... hosting the one day Online Workshop ‘Consciousness is Power’ ... the globe are invited to attend this life transforming ... their consciousness to a higher level. Few days are ... During this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... 2014 A few weeks have passed ... incredible high jump by Inika McPherson is a feat ... the USATF National Championships hosted the best track and ... McPherson, won US Nationals with the 2nd best jump ... for the biggest height over head jump in history. ...
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... has succumbed to the accidental 17 overdoses of radiation, almost ... Norris, from Girvan in Ayrshire, was diagnosed with a brain ... Beatson Oncology Centre in Glasgow, Scotland's largest cancer hospital, which ... 20 years. ,Following a series of 17 radiotherapy sessions ...
... drug Velcade has been banned in England because the Government’s ... (NICE) has refused// to fund treatment, according to last night’s ... that Velcade should not be offered on the NHS to ... a course of Velcade has been estimated to cost between ...
... After all these years, mom was right. She knew broccoli ... this good.// ,“Everyone knows broccoli is good for you ... of some types of cancer. We want to know how ... says Janet V. Cross, Ph.D., Assistant Professor of Pathology at ...
... that they have found the brain’s natural antioxidant defense ... radicals//. ,According to the researchers at the ... from the harmful effects of toxic ‘free radicals’ that ... been associated with aging and certain degenerative brain diseases, ...
... novel look at the brains of adults with autism ... people with the developmental disorder may not communicate// with ... people. ,Researchers from the University of Washington’s Autism ... of the Society for Neuroscience on the first study ...
... break the hopes of a team of eminent plastic surgeons ... who are waiting for the// final approval from The Royal ... complete face transplant which would involve the complete replacement of ... is dead. ,Although the hospital had granted ...
Cached Medicine News:Health News:Cancer patient Dies of Massive Radiation Overdose 2Health News:Brain Regions Do Not Communicate Efficiently in Adults with Autism 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: